Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19399995rdf:typepubmed:Citationlld:pubmed
pubmed-article:19399995lifeskim:mentionsumls-concept:C0024143lld:lifeskim
pubmed-article:19399995lifeskim:mentionsumls-concept:C0209368lld:lifeskim
pubmed-article:19399995lifeskim:mentionsumls-concept:C0677908lld:lifeskim
pubmed-article:19399995lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:19399995lifeskim:mentionsumls-concept:C1522609lld:lifeskim
pubmed-article:19399995lifeskim:mentionsumls-concept:C1554112lld:lifeskim
pubmed-article:19399995pubmed:issue3lld:pubmed
pubmed-article:19399995pubmed:dateCreated2009-4-27lld:pubmed
pubmed-article:19399995pubmed:abstractTextMycophenolate mofetil (MMF) is an alternative to cyclophosphamide for the treatment of lupus nephritis. The precise role of MMF is under ongoing evaluation. This review provides an up-to-date summary of MMF and its use as remission induction and maintenance therapy for lupus nephritis.lld:pubmed
pubmed-article:19399995pubmed:languageenglld:pubmed
pubmed-article:19399995pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19399995pubmed:citationSubsetIMlld:pubmed
pubmed-article:19399995pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19399995pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19399995pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19399995pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19399995pubmed:statusMEDLINElld:pubmed
pubmed-article:19399995pubmed:monthMaylld:pubmed
pubmed-article:19399995pubmed:issn1531-6963lld:pubmed
pubmed-article:19399995pubmed:authorpubmed-author:WalshMichaelMlld:pubmed
pubmed-article:19399995pubmed:authorpubmed-author:SmithKenneth...lld:pubmed
pubmed-article:19399995pubmed:authorpubmed-author:JonesRachel...lld:pubmed
pubmed-article:19399995pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19399995pubmed:volume21lld:pubmed
pubmed-article:19399995pubmed:ownerNLMlld:pubmed
pubmed-article:19399995pubmed:authorsCompleteYlld:pubmed
pubmed-article:19399995pubmed:pagination256-61lld:pubmed
pubmed-article:19399995pubmed:meshHeadingpubmed-meshheading:19399995...lld:pubmed
pubmed-article:19399995pubmed:meshHeadingpubmed-meshheading:19399995...lld:pubmed
pubmed-article:19399995pubmed:meshHeadingpubmed-meshheading:19399995...lld:pubmed
pubmed-article:19399995pubmed:meshHeadingpubmed-meshheading:19399995...lld:pubmed
pubmed-article:19399995pubmed:meshHeadingpubmed-meshheading:19399995...lld:pubmed
pubmed-article:19399995pubmed:meshHeadingpubmed-meshheading:19399995...lld:pubmed
pubmed-article:19399995pubmed:meshHeadingpubmed-meshheading:19399995...lld:pubmed
pubmed-article:19399995pubmed:year2009lld:pubmed
pubmed-article:19399995pubmed:articleTitleWhat is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?lld:pubmed
pubmed-article:19399995pubmed:affiliationRenal Unit, Vasculitis and Lupus Clinic, Box 118, Addenbrooke's Hospital, Hills Road, Cambridge CB2 OQQ, UK.lld:pubmed
pubmed-article:19399995pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19399995pubmed:publicationTypeReviewlld:pubmed
pubmed-article:19399995pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed